Breaking News

Galderma Gains Full Rights To Distribute Restylane

July 11, 2014

Expands footprint with more brands from Valeant.

Galderma S.A. has gained full rights to distribute Restylane, Perlane, Emervel, Sculptra and Dysport from Valeant Pharmaceuticals International, Inc. The expansion into aesthetic and corrective dermatology in the US and Canada completes Galderma's global skin health footprint and extends its leadership in aesthetic medicine worldwide, the company said.

"We at Galderma are delighted to bring Restylane, Perlane, Emervel, and Dysport home in the U.S. and Canada as is the case in dozens of countries around the world. Adding Sculptra to our global portfolio allows us to bring additional indications to our broad range of medical solutions for people with skin needs," said Humberto C. Antunes, CEO and president of Galderma worldwide. "Our science-based approach to fillers and muscle relaxants takes our solutions beyond the aesthetic level to an integral part of holistic medicine, where maintaining, preserving and restoring the health of the skin is as important and as relevant as treating or correcting conditions. With Restylane, Perlane, and Dysport, as well as the innovations to come, we complement our line of prescription and self-medication products to give physicians an arsenal of effective solutions," added Antunes.  

Two of Galderma's most recent innovations in the field, Emervel Classic and Emervel Deep, have been submitted for approval by the FDA and Health Canada and are currently under review.

"The US and Canada represent more than 50 percent of the fast growing global medical aesthetics markets," said Stuart Raetzman, VP of Galderma for North America. "Demographics, social and cultural drivers, as well as an improving economy, make this an ideal time for Galderma to expand its geographic footprint in aesthetic and corrective medicine to the United States and Canada. At Galderma, people come first. We are thrilled to take on board the experienced teams from Valeant Aesthetics and, more than ever, our intent is to preserve the quality of the long-lasting relationships built with doctors. We look forward to partnering with healthcare providers in the growth and expansion of aesthetic and corrective medicine in North America and advancing the care and treatment of patients." 

Related End-User Markets:

  • Erasa

    Erasa's New Evangelist(a)

    January 9, 2017
    Impressed by the performance of its hero SKU, supermodel Linda Evangelista joins the company in a hand's on role.

  • Discourse on Disclosure

    Discourse on Disclosure

    Tom Branna, Editorial Director||January 6, 2017
    Transparency impacts the cleaning industry.

  • The Top Stories of 2016

    The Top Stories of 2016

    December 26, 2016
    The companies and topics that grabbed headlines and your attention this year.

  • On the Edge

    On the Edge

    January 6, 2017
    Expanding beauty brands to watch in 2017

  • The World Comes to Orlando

    The World Comes to Orlando

    Tom Branna, Editorial Director||December 1, 2016
    More than 1,600 chemists traveled to Florida for the IFSCC Congress

  • Perform or Perish

    Perform or Perish

    Christine Esposito, Associate Editor||December 1, 2016
    Success in today’s skin care sector begins with active ingredients, formulated in products that address modern-day issues.